NDA 209388 · Qol Medcl
Gimoti
Metoclopramide Hydrochloride · Nasal
Last checked: Nov 20, 2026Latest source record: Feb 9, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Jun 19, 2020
Approved uses
1
Original approval plus efficacy supplements
Registered trials
192
38 Phase 3, 6 recruiting
FAERS reports
9,040
7,706 serious, 1,097 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: TARDIVE DYSKINESIA Metoclopramide, including GIMOTI, can cause tardive dyskinesia (TD), a potentially irreversible serious movement disorder. In patients treated with metoclopramide, including GIMOTI, the risk of developing TD increases with duration of treatment and total cumulative dosage [see Warnings and Precautions ( 5.1 )] . GIMOTI is contraindicated in patients with a history of TD. Use GIMOTI for the shortest duration of treatment and periodically reassess the need for continued treatment. Immediately discontinue GIMOTI in patients who develop signs or symptoms of TD [see Warnings and Precautions ( 5.1 )] . Avoid a total duration of treatment with metoclopramide products, including GIMOTI, for longer than 12 weeks. If longer-term use is unavoidable, routinely monitor for signs and symptoms of TD [see Warnings and Precautions ( 5.1 )] . WARNING: TARDIVE DYSKINESIA See...
What it is approved for
From the label in effect Feb 20, 2026.
GIMOTI is indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. GIMOTI is a dopamine-2 (D 2 ) antagonist indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. ( 1 ) Limitations of Use : GIMOTI is not recommended for use in: pediatric patients due to the risk of tardive dyskinesia (TD) and other extrapyramidal symptoms as well as the risk of methemoglobinemia in neonates. ( 1 , 8.4 ) moderate or severe hepatic impairment (Child-Pugh B or C), moderate or severe renal impairment (creatinine clearance less than 60 mL/minute), and patients concurrently using strong CYP2D6 inhibitors due to the risk of increased drug exposure and adverse reactions. ( 1 , 5.9 , 7.1 ) Limitations of Use : GIMOTI is not recommended for use in: pediatric patients due to the risk of developing tardive dyskinesia (TD) and other extrapyramidal symptoms as well as the risk of methemoglobinemia in neonates [see Use in Specific Populations ( 8.4 )]. moderate or severe hepatic impairment (Child-Pugh B or C), moderate or severe renal impairment (creatinine clearance less than 60 mL/minute), and patients concurrently using strong CYP2D6 inhibitors due to the risk of increased drug exposure and adverse reactions [see Warnings and Precautions ( 5.9 )]. Limitations of Use : GIMOTI is not recommended for use in: pediatric patients due to the risk of developing tardive dyskinesia (TD) and other extrapyramidal symptoms as well as the risk of methemoglobinemia in neonates [see Use in Specific Populations ( 8.4 )]. moderate or severe hepatic impairment (Child-Pugh B or C), moderate or severe renal impairment (creatinine clearance less than 60 mL/minute), and patients concurrently using strong CYP2D6 inhibitors due to the risk of...
Mechanism: Metoclopramide stimulates motility of the upper gastrointestinal tract without stimulating gastric, biliary, or pancreatic secretions. The exact mechanism of action of metoclopramide in the treatment of gastroesophageal reflux and acute and recurrent diabetic gastroparesis has not been fully established. It seems to sensitize tissues to the action of acetylcholine. The effect of metoclopramide on motility is not dependent on intact vagal innervation, but it can be abolished by anticholinergic drugs. Metoclopramide increases the tone and amplitude of gastric (especially antral) contractions,...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 19, 2020 Original approval · Type 3 - New Dosage Form and Type 4 - New Combination LabelLetterReview
1 products under this application
- GIMOTI · METOCLOPRAMIDE HYDROCHLORIDE EQ 15MG BASE/SPRAY · SPRAY, METERED, NASAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Metoclopramide" as an intervention, any sponsor and status, largest first.
Vanderbilt UniversityAcademic, hospital or other
NCT02625181 · 27,034 participants · Start Jul 2016 · Primary completion Nov 2, 2017
Drug: Propofol; Sevoflurane and 28 more · For: Postoperative Nausea and Vomiting
Sites: Nashville, Tennessee
- Prophylaxis for Aspiration of Gastric Contents.Pivotal-lookingCompleted
King Saud UniversityAcademic, hospital or other
NCT02703896 · 1,920 participants · Start Jan 2012 · Primary completion Jan 2012
Drug: Drug either PPIS or H2RA and prokinetics · For: Pulmonary Aspiration of Gastric Contents
- Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT01594749 · 1,015 participants · Start Sep 24, 2012 · Primary completion Nov 3, 2014
Drug: Fosaprepitant dimeglumine; Fosaprepitant Placebo and 5 more · For: Chemotherapy-Induced Nausea and Vomiting (CINV)
- Effectiveness and Quality of Life Analysis of Palonosetron Against Ondansetron Combined With Dexamethasone and Fosaprepitant in Prevention of Acute and Delayed Emesis Associated to Chemotherapy Moderate and Highly Emetogenic in Breast Cancer.Pivotal-lookingStatus unknown
Instituto Nacional de Cancerologia de MexicoAcademic, hospital or other
NCT03606369 · 560 participants (planned) · Start Nov 5, 2015 · Primary completion Jul 1, 2018
Drug: Palonosetron; Ondansetron · For: Breast Neoplasm; Antineoplastic Agents; Antiemetics and 1 more
Sites: Mexico City, Mexico
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT01636947 · 494 participants · Start Dec 12, 2012 · Primary completion Aug 4, 2014
Drug: Aprepitant; Aprepitant Placebo and 4 more · For: Nausea; Vomiting
- Methoclopramide for Gastroesophageal Reflux in Premature InfantsPivotal-lookingCompleted
Nathalie CharpakAcademic, hospital or other
NCT02907632 · 490 participants · Start Apr 26, 2017 · Primary completion Jan 31, 2019
Drug: Metoclopramide; Placebo · For: Gastroesophageal Reflux
Sites: Bogotá, Colombia
- Metoclopramide, Azithromycin, or Nondrug Pretreatment for UGIB to Reduce Second EndoscopyPivotal-lookingStatus unknown
Waihong ChungAcademic, hospital or other
NCT03840057 · 435 participants (planned) · Start Jul 1, 2020 · Primary completion Jun 2021
Drug: Azithromycin Injection; Metoclopramide Injectable Solution and 1 more · For: Gastro Intestinal Bleeding; Upper Gastrointestinal Bleeding
Sites: Providence, Rhode Island
- The Effect of Aprepitant Reducing Postoperative Nausea and VomitingPivotal-lookingStatus unknown
Hospital General TlahuacGovernment (non-federal)
NCT05772676 · 400 participants · Start Dec 1, 2022 · Primary completion Jan 1, 2023
Drug: Aprepitant · For: Obesity; Nausea and Vomiting, Postoperative
Sites: Mexico City, Mexico
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- tardive dyskinesia2,414
- extrapyramidal disorder1,094
- nausea829
- incorrect drug administration duration691
- off label use605
- diarrhoea507
- vomiting486
- drug ineffective419
- nervous system disorder404
- pyrexia379
- headache371
- tremor365
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 52 |
| 2005 | 66 |
| 2006 | 46 |
| 2007 | 56 |
| 2008 | 57 |
| 2009 | 101 |
| 2010 | 243 |
| 2011 | 2,040 |
| 2012 | 331 |
| 2013 | 353 |
| 2014 | 358 |
| 2015 | 77 |
| 2016 | 116 |
| 2017 | 169 |
| 2018 | 207 |
| 2019 | 297 |
| 2020 | 300 |
| 2021 | 586 |
| 2022 | 905 |
| 2023 | 840 |
| 2024 | 782 |
| 2025 | 647 |
| 2026 | 407 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Gimoti (Metoclopramide HCl)
2024 spending
$4.6M
Beneficiaries
707
2,151 claims
Per beneficiary
$6,437
$210.71 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $374,428 |
| 2022 | $1,393,712 |
| 2023 | $2,946,429 |
| 2024 | $4,551,069 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- The efficacy and safety of metoclopramide in relieving acute migraine attacks compared with other anti-migraine drugs: a systematic review and network meta-analysis of randomized controlled trials.
Abdelmonem H, Abdelhay HM, Abdelwadoud GT, et al. · BMC Neurol 2023 · Systematic Review, Network Meta-Analysis
- Metoclopramide pretreatment attenuates emergency contraceptive-associated nausea.
Ragan RE, Rock RW, Buck HW · Am J Obstet Gynecol 2003 · Clinical Trial, Randomized Controlled Trial
- Metoclopramide for post-pyloric placement of naso-enteral feeding tubes.
Silva CC, Bennett C, Saconato H, et al. · Cochrane Database Syst Rev 2015 · Meta-Analysis, Systematic Review
- Metoclopramide given pre-operatively empties the stomach.
Adelhøj B, Petring OU, Pedersen NO, et al. · Acta Anaesthesiol Scand 1985 · Clinical Trial, Randomized Controlled Trial
- Aspirin with or without an antiemetic for acute migraine headaches in adults.
Kirthi V, Derry S, Moore RA · Cochrane Database Syst Rev 2013 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Can antiemetics really relieve pain?
Derbent A, Uyar M, Demirag K, et al. · Adv Ther 2005 · Randomized Controlled Trial
Sponsor: Qol Medcl
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.